Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease
AUTOR(ES)
Feldman, Howard H
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2117538Documentos Relacionados
- Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial
- Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial
- Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
- Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial
- Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years